Resources
About Us
Home Report
Store
Clinical Trials Market
Clinical Trials Market Size, Share, Forecast, & Trends Analysis by Service (Consulting, Patient Recruitment, Data Management, Regulatory, Site Support) Therapeutic Area (Oncology, Cardiology, Diabetes, Dermatology) Phase, End User - Global Forecast to 2031
Report ID:MRHC - 1041251 Pages: 230 Jun-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursClinical Trials Market Size & Forecast
The Clinical Trials Market is projected to reach $102.20 billion by 2031, growing at a CAGR of 7.2% from 2024 to 2031. The growth of this market can be attributed to various factors, including increasing focus on rare diseases, rise in adoption of personalized medicine, increasing research and development expenditure, and improving recruitment in clinical trials resulting in the retention of participants.
Furthermore, patient-centric clinical trials using the Internet of Medical Things (IoMT), advancements in cloud-based systems for pharmacovigilance, and integration of AI in clinical trials are expected to offer growth opportunities.
Clinical Trial Market Growth Drivers
Increasing Focus on Rare Diseases
Rare diseases are characterized by a wide range of symptoms and signs that vary not only from disease to disease but also from patient to patient suffering from the same condition. According to the National Organization for Rare Disorders, Inc. (U.S.), more than 10,000 rare diseases have affected approximately 30 million Americans. Additionally, according to the European Commission, up to 36 million people in the European Union live with a rare disease, and more than 6000 distinct rare diseases prevail in the European Union. Owing to the increasing cases, various companies have started clinical trials for rare diseases. For instance, Pfizer Inc. (U.S.) conducted clinical trials for hemophilia, transthyretin amyloidosis, and Duchenne muscular dystrophy. Also, in February 2024, AstraZeneca PLC (U.K.) proposed an innovative open-label clinical trial design before regulators for utilizing a control group from prior trials for neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease, instead of a placebo group. This also led to significant interest from the patient community. Thus, the increasing cases of rare diseases are expected to propel the demand for new drugs, which is expected to drive the clinical trials market.
Increasing Pharmaceutical R&D Expenditure
Pharmaceutical companies constantly focus on R&D, which is a core aspect of drug development processes. The biotechnology industry also invests heavily in R&D to cater to the growing demand for innovation and new medical breakthroughs. The importance of R&D is evident due to the rising number of drug approvals. For instance, according to the Congressional Budget Office report of April 2021, the expenditure on research and development has risen by nearly 50 percent in the years 2015 to 2019. Clinical trials have allowed the pharmaceutical industry to develop precision medicines and discover new biomarkers in a shorter period and with low costs. Increasing R&D investments in the pharmaceutical & biotechnology sectors are expected to boost the utilization of advanced clinical trial services, driving the clinical trials market.
Click here to: Get Free Sample Pages of this Report
Clinical Trials Market Trends
Use of Wearable Technology for Clinical Trials
In clinical trials, remote patient monitoring makes it easier for patients to participate and improves recruitment through greater access to diverse patient populations. The use of wearable technology for clinical trials has offered new opportunities for better understanding patients and improving their experience in their journey of clinical trials. Wearable devices have become essential for clinical research as they enable research studies to collect health-related data. For instance, Avantor, Inc. (U.S.), a company providing clinical trial services, reported that around 1,400 clinical trials had been conducted using clinical trials. The studies included therapeutic areas such as cancer, asthma, diabetes, and schizophrenia. Wearable sensors and devices enable the collection of more insightful data for enhancing the understanding of the effects of treatment. Such advantages of wearable technology have further enhanced the use of wearable technology, further easing the way clinical trials are conducted, which is driving the growth of the market.
Incorporating Digital Health Technologies into Clinical Trial
Big Data and AI technologies can work in tandem and serve a major purpose in conducting clinical trials, as AI can assist in analyzing and integrating the mounting data. Advanced analytics and AI are considered the most advanced digital technologies with a high capability to improve clinical research and development productivity. AI technologies are capable of transforming clinical trials, which include developing new patient-centered endpoints, combining phase I and II of clinical trials, and evaluating and collecting real-world data. For instance, in April 2024, Risklick AG (Switzerland) launched Protocol AI, an AI-based software designed to cut down the time required to make a study protocol for a clinical trial. Similarly, in February 2024, Castor Research Inc. (U.S.) collaborated with Microsoft Corporation (U.S.) to bring Microsoft Azure, a modern artificial intelligence tool, into clinical trials. Such instances and the use of AI in modern clinical trials are expected to drive the clinical trials market.
Clinical Trial Market Opportunity
Patient-centric Clinical Trials with the Internet of Medical Things (IoMT)
Internet of Medical Things (IoMT) includes medical devices, applications, and wearable monitors that connect to healthcare information systems that can increase clinical trial efficiency and enhance the ability to support patients throughout their clinical trial journey. Connected devices and applications incorporate the Internet of Medical Things that assist in continuous data monitoring, improve study oversight, reduce site visits, and ensure patient safety, leading to reduced costs and reduced study timelines. Furthermore, the incorporation of electronic health records (EHR) for study design offers participants greater access to trials. Incorporating IoMT has proven to improve the participant experience in clinical trial designs, eventually bringing new and advanced treatments for patients as soon as possible. Such advantages offered by the Internet of Medical Things are expected to drive the growth of the clinical trials market.
Clinical Trials Market Analysis: Key Findings
By Phase: In 2024, the Phase III Segment to Dominate the Clinical Trials Market
Based on phase, the clinical trials market is segmented into pre-clinical trials, phase I, phase II, phase III, and phase IV. In 2024, the phase III segment is expected to account for the largest share of 68.4% of the clinical trials market. Phase III clinical trials use large groups of people to observe the adverse effects of treatment and utilize sophisticated services for studying the efficacy and safety of the drugs. Such factors have contributed to the largest share of the segment. Additionally, many pharmaceutical and biotechnology companies outsource their phase III clinical trials to service providers has supported the largest share of the segment.
By Service Type: In 2024, the Patient Recruitment Services Segment is Projected to Witness the Fastest Growth in the Forecast Period
Based on Service Type, the clinical trials market is segmented into consulting services, safety & regulatory compliance services, site & patient support services, marketing authorization holder-related services, data management services, decentralized clinical trials (DCT) / virtual clinical trials (VCT) services, patient recruitment services, statistical analysis services, bioanalytical services, and other services. The fastest growth rate of the segment is attributed to the increasing number of drugs reaching the phase III clinical trials, the large number of patients pool with required medical conditions, and rising spent on patient recruitment and screening process.
By Therapeutic Area: In 2024, the Oncology Segment to Dominate the Clinical Trials Market
Based on therapeutic area, the clinical trials market is segmented into oncology, infectious diseases, cardiology, metabolism & endocrinology, central nervous system (CNS)/neurology, dermatology, orthopedic and rheumatology, rare diseases, gastroenterology & hepatology, respiratory, women's health, urology, mental health, and ophthalmology. In 2024, the oncology segment is expected to account for the largest share of 33.2% of the clinical trials market. The largest share of the segment is attributed to the increasing prevalence of cancer, increasing R&D for cancer drugs, and technological advancements in cancer treatments. For instance, cancer is the leading cause of death worldwide. The most common cancers are breast, lung, colon, rectum, and prostate cancers. According to the World Health Organization February 2022 report, approximately 10 million deaths in 2020 were caused due to cancer.
By End Users: In 2024, the Pharmaceuticals & Biotechnology Companies Segment to Dominate the Clinical Trials Market
Based on end users, the clinical trials market is segmented into pharmaceuticals & biotechnology companies, medical device companies, and other end users. In 2024, the pharmaceuticals & biotechnology companies’ segment is expected to account for the largest share of the clinical trials market. The largest share of the segment is attributed to the high investments in R&D for the development of new drugs and therapies by pharmaceutical and biotechnology companies, increasing demand for innovative therapies for various diseases leading to high demand from pharmaceutical and biotechnology companies for outsourcing clinical trials for bringing new treatments to market.
Geographical Analysis
In 2024, North America is expected to account for the largest share of 41.6% of the clinical trials market. North America's significant market share is attributed to an increase in R&D investments, a rise in the adoption of new technologies in clinical trials, and the presence of key market players in this region. For instance, in March 2024, Laboratory Corporation of America Holdings (U.S.) launched pTau217, a biomarker test for accelerating the path to diagnosis of Alzheimer’s disease, which is also used for clinical trials. Additionally, according to the National Library of Medicine (U.S.), as of April 2024, approximately 149,999 clinical trial studies are registered in the U.S.
Clinical Trials Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years 2020–2024. The key players operating in the global clinical trials market are Laboratory Corporation of America Holdings (U.S), Medpace, Inc. (U.S), Charles River Laboratories International, Inc. (U.S.), IQVIA Inc. (U.S.), Parexel International Corporation (U.S.), Syneos Health (U.S), ICON plc (Ireland), WuXi AppTec Co., Ltd. (China), Thermo Fisher Scientific Inc. (U.S), Fortrea Inc. (U.S), Celerion Inc. (U.S.), Novotech Health Holdings (Australia), SGS Société Générale de Surveillance SA. (Switzerland), CTI Clinical Trial and Consulting, Inc. (U.S.), and Linical USA, Inc. (U.S.).
Clinical Trials Industry Overview: Latest Developments from Key Industry Players
-
In April 2024, Parexel International Corporation (MA) Corporation (U.S.) partnered with Palantir Technologies Inc. (U.S.) to utilize AI to enhance and accelerate the delivery of safe and effective clinical trials while maintaining the highest level of regulatory integrity and safety.
-
In June 2023, Syneos Health (U.S.) collaborated with uMotif Limited (U.K.) to accelerate clinical trials and to bring new therapies for patients through an efficient and faster end-to-end digital system that includes Electronic Patient-reported Outcomes (ePRO), and Electronic Clinical Outcome Assessment (eCOA) capabilities.
- In September 2023, ICON plc (Ireland) launched a next-generation Clinical Trial Tokenisation solution, which combines all the important components for allowing the collation of patient data in a discreet, confidential, and non-intrusive way with Privacy Protected Record Linkage (PPRL) across source and time.
- In November 2023, Ichor Life Sciences, Inc. (U.S.) launched Ichor Clinical Trials Services. The newly launched service will combine a spectrum of clinical trial solutions ranging from individual services to full CRO services.
Clinical Trials Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
230 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
7.2% |
|
Estimated Market Size (Value) |
$102.20 Billion by 2031 |
|
Segments Covered |
By Phase
By Service Type
By Therapeutic Area
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Poland, Belgium, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
|
Key Companies |
The key players operating in the global clinical trials market are Laboratory Corporation of America Holdings (U.S), Medpace, Inc. (U.S), Charles River Laboratories International, Inc. (U.S.), IQVIA Inc. (U.S.), Parexel International Corporation (U.S.), Syneos Health (U.S), ICON plc (Ireland), WuXi AppTec Co., Ltd. (China), Thermo Fisher Scientific Inc. (U.S), Fortrea Inc. (U.S), Celerion Inc. (U.S.), Novotech Health Holdings (Australia), SGS Société Générale de Surveillance SA. (Switzerland), CTI Clinical Trial and Consulting, Inc. (U.S.), and Linical USA, Inc. (U.S.). |
Key questions answered in the clinical trials market report:
The Clinical Trials Market refers to the industry involved in conducting research studies to evaluate the safety and efficacy of drugs, treatments, or medical devices before they are brought to market.
The Clinical Trials Market was valued at $67.8 billion in 2023 and is projected to reach $102.20 billion by 2031, driven by advancements in drug development, AI integration, and personalized medicine.
The Clinical Trials Market is forecasted to grow at a CAGR of 7.2% from 2024 to 2031, driven by rising R&D spending, personalized medicine, and increasing focus on rare diseases.
The Clinical Trials Market size is projected to grow from $67.8 billion in 2023 to $102.20 billion by 2031, primarily driven by rising demand for advanced drug development and clinical research services.
Key companies in the Clinical Trials Market include Laboratory Corporation of America, Medpace, Charles River Laboratories, IQVIA, Parexel, Syneos Health, ICON, and WuXi AppTec.
The market trend includes increasing use of wearable technologies, AI, cloud-based platforms, decentralized clinical trials, and the focus on patient-centric approaches for better data collection and trial outcomes.
Key drivers include the increasing focus on rare diseases, rising R&D expenditure, adoption of personalized medicine, and advancements in AI and digital health technologies.
The Clinical Trials Market is segmented by phase (Pre-clinical, Phase I, II, III, IV), service type (consulting, patient recruitment, data management), therapeutic area (oncology, cardiology, CNS), and end-users (pharma & biotech companies).
Globally, the Clinical Trials Market is expected to experience robust growth, with North America accounting for the largest market share, driven by high R&D investment and the adoption of new technologies in clinical research.
The Clinical Trials Market is projected to grow at a CAGR of 7.2% from 2024 to 2031, with increasing investments in personalized medicine, rare disease treatments, and remote patient monitoring driving the expansion.
The Clinical Trials Market is projected to grow at a CAGR of 7.2% during the forecast period from 2024 to 2031.
North America holds the highest market share, accounting for 41.6% of the Clinical Trials Market in 2024, driven by strong R&D activities and technological advancements.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Focus on Rare Diseases
4.2.2. Rise in Adoption of Personalized Medicine
4.2.3. Increasing Research and Development Expenditure
4.2.4. Improvement in Recruitment Process in Clinical Trials Resulting in Retention of Participants
4.3. Restraints
4.3.1. The Time-consuming Process of Clinical Trials
4.3.2. Stringent Regulations and Changing Laws Increasing the Complexity of Clinical Trials
4.4. Opportunities
4.4.1. Patient-centric Clinical Trials Using Internet of Medical Things (IoMT)
4.4.2. Advancements in Cloud-based Systems for Pharmacovigilance
4.2.3. Integration of AI in Clinical Trial Site Selection
4.5. Challenges
4.5.1. Lack of Skilled Professionals in Clinical Trial
4.5.2. Complexity in Clinical Trial Protocols
4.5.3. Lack of Participation from Several Ethnic Groups
4.6. Trends
4.6.1. Incorporating Digital Health Technologies into Clinical Trial
4.6.2. Use of Wearable Technology for Clinical Trials
4.6.3. Automated Clinical Trials
4.6.4. Decentralized Clinical Trials
4.6.5. AI Modeling and Forecasting Patient Enrichment & Recruitment
4.6.6. AI-enabled Clinical Trial Analytics
4.7. Factor Analysis
4.8. Regulatory Analysis
4.8.1. U.S.
4.8.2. Canada
4.8.3. Europe
4.8.4. China
4.8.5. Japan
4.8.6. India
4.8.7. Latin America
4.8.8. Middle East
4.9. Case Studies
4.10. Porter’s Five Forces Analysis
5. Clinical Trials Market Assessment—by Phase
5.1. Overview
5.2. Pre-clinical Trial
5.3. Phase I
5.4. Phase II
5.5. Phase III
5.6. Phase IV
6. Clinical Trials Market Assessment—by Service Type
6.1. Overview
6.2. Consulting Services
6.3. Safety & Regulatory Compliance Services
6.4. Site & Patient Support Services
6.5. Marketing Authorization Holder Related Services
6.6. Data Management Services
6.7. Decentralized Clinical Trials (DCT)/Virtual Clinical Trials (VCT) Services
6.8. Patient Recruitment Services
6.9. Statistical Analysis Services
6.10. Bioanalytical Services
6.11. Other Services
7. Clinical Trials Market Assessment—by Therapeutic Area
7.1. Overview
7.2. Oncology
7.3. Infectious Diseases
7.4. Cardiology
7.5. Metabolism & Endocrinology
7.6. Central Nervous System (CNS)/Neurology
7.7. Dermatology
7.8. Orthopedic and Rheumatology
7.9. Rare Diseases
7.10. Gastroenterology & Hepatology
7.11. Respiratory
7.12. Women's Health
7.13. Urology
7.14. Mental Health
7.15. Ophthalmology
8. Clinical Trials Market Assessment—by End User
8.1. Overview
8.2. Pharmaceuticals & Biotechnology Companies
8.3. Medical Device Companies
8.4. Other End Users
9. Clinical Trials Market Assessment—by End User
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Poland
9.3.7. Belgium
9.3.8. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis/Market Rankings of Key Players (2023)
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
11.1. Laboratory Corporation of America Holdings
11.2. Medpace, Inc.
11.3. Charles River Laboratories International, Inc.
11.4. IQVIA Inc.
11.5. Parexel International Corporation
11.6. Syneos Health
11.7. ICON plc
11.8. WuXi AppTec Co., Ltd.
11.9. Thermo Fisher Scientific Inc.
11.10. Fortrea Inc.
11.11. Celerion Inc.
11.12. Novotech Health Holdings
11.13. SGS Société Générale de Surveillance SA.
11.14. CTI Clinical Trial and Consulting, Inc.
11.15. Linical USA, Inc.
(Note: SWOT analyses of the top 5 companies will be provided.)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Global Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 2 Global Pre-clinical Trial Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Global Phase I Clinical Trials Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Phase II Clinical Trials Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Global Phase III Clinical Trials Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Phase IV Clinical Trials Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 8 Global Clinical Trials Consulting Services Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Global Clinical Trials Safety & Regulatory Compliance Services Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Clinical Trials Site & Patient Support Services Market, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Clinical Trials Marketing Authorization Holder Related Services Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Clinical Trials Data Management Services Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Decentralized Clinical Trials (DCT) / Virtual Clinical Trials (VCT) Services Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Clinical Trials Patient Recruitment Services Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Clinical Trials Statistical Analysis Services Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Clinical Trials Bioanalytical Services Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Other Clinical Trials Services Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 19 Global Clinical Trials Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 20 Global Clinical Trials Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 21 Global Clinical Trials Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Clinical Trials Market for Metabolism & Endocrinology, by Country/Region, 2022–2031 (USD Million)
Table 23 Global Clinical Trials Market for Central Nervous System (CNS)/Neurology, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Clinical Trials Market for Dermatology, by Country/Region, 2022–2031 (USD Million)
Table 25 Global Clinical Trials Market for Orthopedic and Rheumatology, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Clinical Trials Market for Rare Diseases, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Clinical Trials Market for Gastroenterology & Hepatology, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Clinical Trials Market for Respiratory, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Clinical Trials Market for Women's Health, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Clinical Trials Market for Urology, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Clinical Trials Market for Mental Health, by Country/Region, 2022–2031 (USD Million)
Table 32 Global Clinical Trials Market for Ophthalmology, by Country/Region, 2022–2031 (USD Million)
Table 33 Global Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 34 Global Clinical Trials Market for Pharmaceuticals & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 35 Global Clinical Trials Market for Medical Device Companies, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Clinical Trials Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 37 Global Clinical Trials Market, by Country/Region, 2022–2031 (USD Million)
Table 38 North America: Clinical Trials Market, by Country, 2022–2031 (USD Million)
Table 39 North America: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 40 North America: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 41 North America: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 42 North America: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 43 U.S.: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 44 U.S.: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 45 U.S.: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 46 U.S.: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 47 Canada: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 48 Canada: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 49 Canada: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 50 Canada: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 51 Europe: Clinical Trials Market, by Country/Region, 2022–2031 (USD Million)
Table 52 Europe: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 53 Europe: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 54 Europe: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 55 Europe: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 56 Germany: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 57 Germany: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 58 Germany: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 59 Germany: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 60 France: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 61 France: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 62 France: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 63 France: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 64 U.K.: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 65 U.K.: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 66 U.K.: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 67 U.K.: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 68 Italy: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 69 Italy: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 70 Italy: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 71 Italy: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 72 Spain: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 73 Spain: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 74 Spain: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 75 Spain: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 76 Poland: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 77 Poland: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 78 Poland: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 79 Poland: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 80 Belgium: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 81 Belgium: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 82 Belgium: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 83 Belgium: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 84 Rest of Europe: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 85 Rest of Europe: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 86 Rest of Europe: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 87 Rest of Europe: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 88 Asia-Pacific: Clinical Trials Market, by Country/Region, 2022–2031 (USD Million)
Table 89 Asia-Pacific: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 90 Asia-Pacific: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 91 Asia-Pacific: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 92 Asia-Pacific: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 93 Japan: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 94 Japan: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 95 Japan: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 96 Japan: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 97 China: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 98 China: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 99 China: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 100 China: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 101 India: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 102 India: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 103 India: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 104 India: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 105 Australia: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 106 Australia: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 107 Australia: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 108 Australia: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 109 South Korea: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 110 South Korea: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 111 South Korea: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 112 South Korea: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 113 Rest of Asia-Pacific: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 114 Rest of Asia-Pacific: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 115 Rest of Asia-Pacific: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 116 Rest of Asia-Pacific: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 117 Latin America: Clinical Trials Market, by Country/Region, 2022–2031 (USD Million)
Table 118 Latin America: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 119 Latin America: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 120 Latin America: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 121 Latin America: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 122 Brazil: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 123 Brazil: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 124 Brazil: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 125 Brazil: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 126 Mexico: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 127 Mexico: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 128 Mexico: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 129 Mexico: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 130 Rest of Latin America: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 131 Rest of Latin America: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 132 Rest of Latin America: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 133 Rest of Latin America: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 134 Middle East & Africa: Clinical Trials Market, by Phase, 2022–2031 (USD Million)
Table 135 Middle East & Africa: Clinical Trials Market, by Service Type, 2022–2031 (USD Million)
Table 136 Middle East & Africa: Clinical Trials Market, by Therapeutic Area, 2022–2031 (USD Million)
Table 137 Middle East & Africa: Clinical Trials Market, by End User, 2022–2031 (USD Million)
Table 138 Recent Developments, by Company, 2021–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Clinical Trials Market, by Phase, 2024 VS. 2031 (USD Million)
Figure 8 Global Clinical Trials Market, by Service Type, 2024 VS. 2031 (USD Million)
Figure 9 Global Clinical Trials Market, by Therapeutic Area, 2024 VS. 2031 (USD Million)
Figure 10 Global Clinical Trials Market, by End User, 2024 VS. 2031 (USD Million)
Figure 11 Global Clinical Trials Market, by Geography
Figure 12 Impact Analysis: Clinical Trials Market
Figure 13 Global Clinical Trials Market, by Phase, 2024 VS. 2031 (USD Million)
Figure 14 Global Clinical Trials Market, by Service Type, 2024 VS. 2031 (USD Million)
Figure 15 Global Clinical Trials Market, by Therapeutic Area, 2024 VS. 2031 (USD Million)
Figure 16 Global Clinical Trials Market, by End User, 2024 VS. 2031 (USD Million)
Figure 17 Global Clinical Trials Market, by Geography, 2024 VS. 2031 (USD Million)
Figure 18 North America: Clinical Trials Market Snapshot
Figure 19 Europe: Clinical Trials Market Snapshot
Figure 20 Asia-Pacific: Clinical Trials Market Snapshot
Figure 21 Latin America: Clinical Trials Market Snapshot
Figure 22 Key Growth Strategies Adopted by Leading Players, 2021–2024
Figure 23 Global Clinical Trials Market: Competitive Benchmarking, by Service Type
Figure 24 Global Clinical Trials Market: Competitive Benchmarking, by Geography
Figure 25 Global Clinical Trials Market: Competitive Dashboard
Figure 26 Global Clinical Trials Market: Market Share Analysis/ Market Ranking, By Players (2023)
Figure 27 Laboratory Corporation of America Holdings: Financial Overview (2023)
Figure 28 Medpace, Inc.: Financial Overview (2023)
Figure 29 Charles River Laboratories International, Inc.: Financial Overview (2023)
Figure 30 IQVIA Inc.: Financial Overview (2023)
Figure 31 WuXi AppTec Co., Ltd.: Financial Overview (2023)
Figure 32 Thermo Fisher Scientific Inc.: Financial Overview (2023)
Figure 33 Fortrea Inc.: Financial Overview (2022)
Figure 34 Linical USA, Inc.: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Surgical Drills Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Nov-2024
eClinical Solutions Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jun-2024
Clinical Trial Supplies Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Feb-2024
Clinical Lab Automation Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Jan-2024
